http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103819483-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D493-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D493-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 |
| filingDate | 2014-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103819483-B |
| titleOfInvention | The control medicine of pulmonary hypertension and synthesis thereof and application |
| abstract | The invention discloses compound, wherein R shown in general structure (I)n 1 , Rn 2 independently selected from-CHn 3 ,-CHn 2 cHn 3 .This compound phenylacetic acid derivatives and benzaldehyde derivative is carried out Perkin under the effect of acetic anhydride and basic catalyst be obtained by reacting intermediate, and intermediate and isosorbide mononitrate carry out condensation reaction and obtain compound shown in general structure (I).The present invention is by the structural modification to the different trans-resveratrol of primer, and energy enhanced stability, increase its bioavailability, and impel prolonged drug, the trans-resveratrol improving hydroxyl structure is oxidizable, the shortcoming of not easily preserving. |
| priorityDate | 2014-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 84.